@amitvkhera @psychgenomics Aducanumab (antibody against AB) first AD drug to show (highly significant) effect on plaques on PET and had nominal effect on MMSE in phase 2 of prodromal to mild AD (https://t.co/L7OFn0yBEn): results from phase 3 in 2019
The academic journal article that the about article was based on...https://t.co/erNJqgINrp. My cousin Robert Scannevin, is one of the authors!
@jordixiol @Dereklowe @MaverickNY @WilliamGerber1 More info on Aducanumab: https://t.co/XwUXpLNm0q
@Shaleo24 shush, here it is : https://t.co/wSqcgnEm7R THANK YOU LOOOOVE !
With aducanumab in the news, a look back at the paper in Nature: https://t.co/zTCtRES8zq $BIIB https://t.co/ihG2LB9jVy
RT @OrenoSource: 臨床試験薬、アルツハイマー病に「目覚ましい」効果 AFP https://t.co/y67KRfjuVF アミロイドβに対する抗体薬aducanumabの投与によりアミロイド斑が除去されたという臨床試験結果（nature）→ https:/…
RT @LiviSloss: New therapy success for Alzheimer's! https://t.co/gtb4AaoIkk
RT @yuji_ikegaya: 【認知症の免疫療法 ついに成功か!?】アミロイドβ凝集体に対するヒトモノクローナル抗体を、毎月一回静脈注射すると、脳のアミロイドβが減少し、アルツハイマー型認知症の症状の進行を遅らせることができたそうです。今朝の『ネイチャー』誌より→http…
The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease https://t.co/FE5w2mtFhx
The amyloid hypothesis: Aβ plaques shrink & cognitive function improves with aducanumab in AD https://t.co/0KdJJztga3
Synaptic dysfunction https://t.co/1yJngfFw7w #HelterSkelterChallenge
Aducanumab the way to go for the treatment of Alzheimer's diseases? #dementia https://t.co/ZSuzvMT3i7
The hype has died down, but I'm hopeful for positive #aducanumab PhIII data in 2020. #Alzheimers https://t.co/OsJlLrJTYW https://t.co/gpTuYnQ1ft
REMARKABLE! Hope it works!!! https://t.co/GSkkohkXJN
Exciting news - potential drug to slow progression of Alzheimer's dementia. https://t.co/ipyn3PNQye
Alzheimer’s disease: deposits of Aβ plaques, neurofibrillary tangles, synaptic dysfunction & neurodegeneration https://t.co/o5YpvP3AYa
The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease https://t.co/ayUA9IBXcH
The antibody aducanumab reduces Aβ plaques in #Alzheimer’s disease (from Sept 2016) https://t.co/SH6RTw2IGN
Good catch @NathanStall. Table 2 in fact indicates 2 in the placebo group had ARIA (contrary to the text) https://t.co/GlzEjer6sY #GeriMedJC
Fig 2c: change from baseline MMSE in aducanumab-treated patients https://t.co/G1tIldVqVZ #GeriMedJC https://t.co/Rhp5JILn84
Fig 2c: change from baseline CDR-SB in aducanumab-treated patients https://t.co/G1tIled2kz #GeriMedJC https://t.co/gv2FmagJMc
Fig 2a: amyloid plaque reduction, SUVR values https://t.co/G1tIldVqVZ #GeriMedJC https://t.co/DIWB2UzVPG
Table 2: most common adverse effects were amyloid-related imaging abnormalities, headache, UTI, URTI https://t.co/G1tIled2kz #GeriMedJC https://t.co/nnZYxDtEGS
Figure 1: Treatment reduced brain Aβ plaques in a dose- and time-dependent fashion. https://t.co/G1tIled2kz #GeriMedJC https://t.co/n1OVWzbBQj
Clinical assessments were exploratory as the study was not powered to detect clinical change. https://t.co/G1tIldVqVZ #GeriMedJC
Sensitivity analyses done using a mixed model for repeated measures. https://t.co/G1tIldVqVZ #GeriMedJC
Nominal P values presented with no adjustments for multiple comparisons. https://t.co/G1tIldVqVZ #GeriMedJC
Primary analyses based on observed data with no imputation for missing values. Fair? https://t.co/G1tIldVqVZ #GeriMedJC
Table 1. Baseline characteristics. Like your patients? https://t.co/G1tIled2kz #GeriMedJC https://t.co/iYLKpP8Opt
N = 165. Of these patients, 125 completed and 40 discontinued treatment https://t.co/G1tIldVqVZ #GeriMedJC
Intervention: IV aducanumab (1, 3, 6, or 10 mg/kg) or placebo once every 4 weeks for 52 weeks https://t.co/G1tIldVqVZ #GeriMedJC
Inclusion criteria: 50–90 years old and meeting clinical criteria for either prodromal or mild AD https://t.co/G1tIldVqVZ #GeriMedJC
Study design: multicentre, randomized, 12-month, double-blind, placebo-controlled, multiple-dose https://t.co/G1tIled2kz #GeriMedJC
Objective: evaluate safety and tolerability of aducanumab in prodromal AD or mild AD #dementia https://t.co/G1tIled2kz #GeriMedJC
.@NathanStall starts #GeriMedJC discussion with study of interim results of aducanumab trial for Alzheimer's disease https://t.co/XMDZjDE91N
Need links to the article for #GeriMedJC? Starts in 5 mins! https://t.co/XMDZjDE91N https://t.co/LXNufPoBqf
Source: https://t.co/wZBV6W1YkE (h/t >> https://t.co/57zsviQgOu) https://t.co/yDMkbX8ap5
RT @yuji_ikegaya: 【認知症の免疫療法 ついに成功か!?】アミロイドβ凝集体に対するヒトモノクローナル抗体を、毎月一回静脈注射すると、脳のアミロイドβが減少し、アルツハイマー型認知症の症状の進行を遅らせることができたそうです。今朝の『ネイチャー』誌より→http…
RT @ibrahimimam2000: Aducanumab reduces Aβ plaques in #AlzheimersDisease https://t.co/0poSjfnFsm
RT @ibrahimimam2000: Aducanumab reduces Aβ plaques in #AlzheimersDisease https://t.co/0poSjfnFsm
Aducanumab reduces Aβ plaques in #AlzheimersDisease https://t.co/0poSjfnFsm
RT @yuji_ikegaya: 【認知症の免疫療法 ついに成功か!?】アミロイドβ凝集体に対するヒトモノクローナル抗体を、毎月一回静脈注射すると、脳のアミロイドβが減少し、アルツハイマー型認知症の症状の進行を遅らせることができたそうです。今朝の『ネイチャー』誌より→http…
L'anticós aducanumab redueix les plaques Aβ en la malaltia d'Alzheimer. https://t.co/l2SLw79Bfw https://t.co/SiU3WKr70w
The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease Jeff Sevigny, Ping Chiao, Thierry Bussière,... https://t.co/bjeufJpiz2
RT @FutureofHealth: #Alzheimer #AlzheimersAwareness antibody aducanumab https://t.co/Nvg3N7S6KG
#Alzheimer #AlzheimersAwareness antibody aducanumab https://t.co/Nvg3N7S6KG
RT @MMUNeuroscience: Hard not to get excited about the latest results using #aducanumab in #Alzheimers patients! Excited for Phase 3. https…
RT @cynthiaermshar: The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease https://t.co/by0CdIPjaR #EndAlz #FindACure https://t.…
The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease https://t.co/by0CdIPjaR #EndAlz #FindACure https://t.co/FLjSBqYJ1Y
RT @Hesso_F_Sci: aducanumab, which selecively bind aggergated amyloid beta was claimed to work. https://t.co/qNqXWGNPo4 https://t.co/nDmVeB…
aducanumab, which selecively bind aggergated amyloid beta was claimed to work. https://t.co/qNqXWGNPo4 https://t.co/nDmVeB3vql
Aducanumab reduces amyloid Aß- plaques in (early stage) Alzheimer´s Disease according (small) phase 1B- study https://t.co/1cl4Aa8rTA
"The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease" (Nature 537 (2016) 50-56) https://t.co/jZaYQ1jN2R 抗体医薬の件、こちらも現代化学12月号から。
RT @NicholasCT: Rise of the biologics. https://t.co/8WMH82giUd
RT @yuji_ikegaya: 【認知症の免疫療法 ついに成功か!?】アミロイドβ凝集体に対するヒトモノクローナル抗体を、毎月一回静脈注射すると、脳のアミロイドβが減少し、アルツハイマー型認知症の症状の進行を遅らせることができたそうです。今朝の『ネイチャー』誌より→http…
The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease https://t.co/wvwtvCyqe0
The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease https://t.co/Tl4wwUSsP3
Glimmer of hope? https://t.co/Z9j2CJs5Vl
Article 1: aducanumab for Alzheimer's dementia #geriupdate16 @dellightd https://t.co/motuiwGfIX https://t.co/WdD2z9j5a7
Una nueva luz en la batalla frente a la enfermedad de Alzheimer: https://t.co/OwvDTTj1YN.
EVIDENCE: The antibody Aducanumab reduces amyloid plaques in Alzheimer's Disease. https://t.co/c9K44uVTDO @hthsci4bb3 #hittingtheheadlines
Hope. https://t.co/v1YD0WdWaI
The antibody #Aducanumab reduces Aβ plaques in #Alzheimers; needs confirmation from ongoing phase 3 clinical trial. https://t.co/is66xROPB6
The antibody #aducanumab reduces Aβ plaques in #Alzheimer's disease. https://t.co/4X9lMjnyTB
Resultados del ensayo preclínico fase Ib de aducanumab, vía de investigación esperanzadora contra el #Alzheimer https://t.co/PZ95LdCoK8
RT @nature: An antibody reduces Aβ deposits in the brains of patients with mild Alzheimer’s disease https://t.co/qaf5AzwNHn https://t.co/N7…
RT @nature: An antibody reduces Aβ deposits in the brains of patients with mild Alzheimer’s disease https://t.co/qaf5AzOoyV https://t.co/wd…
New #Drug Shows Promise In Small Trial For #Alzheimer’s #disease https://t.co/3AVD824IGH #health
RT @nature: An antibody reduces Aβ deposits in the brains of patients with mild Alzheimer’s disease https://t.co/qaf5AzOoyV https://t.co/wd…
Biogen creating some great buzz with aducanumab. Would be a great advance in Alzheimer's therapy if things hold true https://t.co/tA5zYskDZG
RT @AshwinVV: Attacking amyloid with aducanumab. There's hope for Alzheimer's yet https://t.co/DIZMGYU4ij @NatureMedicine https://t.co/eLOW…
@joseluis_pa un paper calentito sobre el aducanumab, la inmunoterapias avanzan...pero, falta mucho https://t.co/6psx16tm9k
The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease https://t.co/OiZ0pzF8ah
RT @nature: An antibody reduces Aβ deposits in the brains of patients with mild Alzheimer’s disease https://t.co/qaf5AzwNHn https://t.co/N7…
RT @yuji_ikegaya: 【認知症の免疫療法 ついに成功か!?】アミロイドβ凝集体に対するヒトモノクローナル抗体を、毎月一回静脈注射すると、脳のアミロイドβが減少し、アルツハイマー型認知症の症状の進行を遅らせることができたそうです。今朝の『ネイチャー』誌より→http…
RT @yuji_ikegaya: 【認知症の免疫療法 ついに成功か!?】アミロイドβ凝集体に対するヒトモノクローナル抗体を、毎月一回静脈注射すると、脳のアミロイドβが減少し、アルツハイマー型認知症の症状の進行を遅らせることができたそうです。今朝の『ネイチャー』誌より→http…
Aducanumab positive Phase I-B results - optimistic, but remember why Phase III is gold-standard! https://t.co/3GRopgvs0J
RT @nature: An antibody reduces Aβ deposits in the brains of patients with mild Alzheimer’s disease https://t.co/qaf5AzwNHn https://t.co/N7…
RT @nature: An antibody reduces Aβ deposits in the brains of patients with mild Alzheimer’s disease https://t.co/qaf5AzwNHn https://t.co/N7…
New research on antibody: Could be massive #breakthrough for #Alzheimers Is a cure close?🤔 https://t.co/qAl1p8IRIT #medicine #health
RT @denaturant: アルツハイマー薬として、Ab凝集体をターゲットにした王道の抗体はあんがい難航しているけど、aducanumabが最初の薬になるのかな。 https://t.co/smSVjIpzX6
アルツハイマー薬として、Ab凝集体をターゲットにした王道の抗体はあんがい難航しているけど、aducanumabが最初の薬になるのかな。 https://t.co/smSVjIpzX6
RT @yuji_ikegaya: 【認知症の免疫療法 ついに成功か!?】アミロイドβ凝集体に対するヒトモノクローナル抗体を、毎月一回静脈注射すると、脳のアミロイドβが減少し、アルツハイマー型認知症の症状の進行を遅らせることができたそうです。今朝の『ネイチャー』誌より→http…
And in case you missed it, there was that study exploring immunotherapy for Alzheimer's: https://t.co/KWuPkPxyEZ
The antibody aducanumab reduces Aβ plaques in Alzheimer's disease. - PubMed - NCBI https://t.co/vB46jA71p9
RT @PDP_UAB: Interesting publication on #Alzheimer research in @nature The antibody aducanumab reduces Aβ plaques https://t.co/yDHbO8MZ5R
RT @Heart_BMJ: The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease : Nature : Nature Research https://t.co/HT71X3pBWi
RT @Heart_BMJ: The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease : Nature : Nature Research https://t.co/HT71X3pBWi
RT @Heart_BMJ: The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease : Nature : Nature Research https://t.co/HT71X3pBWi
RT @Heart_BMJ: The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease : Nature : Nature Research https://t.co/HT71X3pBWi
RT @PDP_UAB: Interesting publication on #Alzheimer research in @nature The antibody aducanumab reduces Aβ plaques https://t.co/yDHbO8MZ5R
RT @PDP_UAB: Interesting publication on #Alzheimer research in @nature The antibody aducanumab reduces Aβ plaques https://t.co/yDHbO8MZ5R
RT @Heart_BMJ: The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease : Nature : Nature Research https://t.co/HT71X3pBWi
RT @Heart_BMJ: The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease : Nature : Nature Research https://t.co/HT71X3pBWi
RT @nature: An antibody reduces Aβ deposits in the brains of patients with mild Alzheimer’s disease https://t.co/qaf5AzwNHn https://t.co/N7…
RT @Heart_BMJ: The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease : Nature : Nature Research https://t.co/HT71X3pBWi
RT @Heart_BMJ: The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease : Nature : Nature Research https://t.co/HT71X3pBWi
RT @Heart_BMJ: The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease : Nature : Nature Research https://t.co/HT71X3pBWi